Among FMF patients who received anti-IL-1 therapy, fibrinogen, NLR, and RDW, as well as inflammatory parameters such as ESR and CRP levels, were higher in patients with amyloidosis than those without amyloidosis. This evidence concerns the gene IL1A and amyloidosis.